New hope for kids with rare ALK+ cancers: brigatinib trial opens

NCT ID NCT04925609

Recruiting now Disease control Sponsor: Princess Maxima Center for Pediatric Oncology Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 19 times

Summary

This study tests a drug called brigatinib in children and young adults (ages 1 to 25) with ALK-positive cancers, including anaplastic large cell lymphoma and inflammatory myofibroblastic tumors. The goal is to find the best dose and see how safe and effective the drug is. About 65 participants will take brigatinib pills daily for up to 2 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institut Gustave Roussy
RECRUITING

Paris, 94805, France

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
Princess Máxima Center for Pediatric Oncology
RECRUITING

Utrecht, Utrecht, 3584 CS, Netherlands

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE INFLAMMATORY MYOFIBROBLASTIC TUMOR OTHER SOLID TUMOR